Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis

IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2024-09-17 DOI:10.1177/13524585241274580
Ellen O’Donnell, Allison Schuette, Michael Waltz, Gregory Aaen, Leslie Benson, Mark Gorman, Timothy Lotze, Soe Mar, Jayne Ness, Moses Rodriguez, Jan-Mendelt Tillema, Teri Schreiner, Yolanda Wheeler, T Charles Casper, Tanuja Chitnis
{"title":"Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis","authors":"Ellen O’Donnell, Allison Schuette, Michael Waltz, Gregory Aaen, Leslie Benson, Mark Gorman, Timothy Lotze, Soe Mar, Jayne Ness, Moses Rodriguez, Jan-Mendelt Tillema, Teri Schreiner, Yolanda Wheeler, T Charles Casper, Tanuja Chitnis","doi":"10.1177/13524585241274580","DOIUrl":null,"url":null,"abstract":"Background and Objectives:This survey study aimed to (1) identify patient/family research priorities in pediatric-onset multiple sclerosis (POMS), and (2) delineate optimized methods for research study/clinical trials design, engagement, and implementation.Methods:Participants were as follows: (1) parents of a child (<18 years) with POMS enrolled in a national registry, (2) adolescents (13–17 years) with POMS in the registry, and (3) adults (18–40 years) with POMS receiving care at a registry affiliated clinic. Of 293 eligible participants, 192 completed surveys.Results:Experiences with health care and medications were generally positive but there remain areas of priority improvement. Incentives to participate in clinical trials included medications previously tested and in pill form, bloodwork/study visits required ⩾ every 3 months, cognitive testing ⩽1 hour, compensation for travel and time, ability to continue current multiple sclerosis (MS) medication, option to take study medication if on placebo, and individualized study feedback. Priorities for clinical research were (1) psychosocial impact, (2) cognitive/academic impact, (3) environmental risk, and (4) nutrition.Conclusions:Results highlighted the importance of a holistic approach to study design and a focus on the impact of disease on daily life to best engage patients and families in POMS clinical trials and research.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":"1 1","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241274580","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objectives:This survey study aimed to (1) identify patient/family research priorities in pediatric-onset multiple sclerosis (POMS), and (2) delineate optimized methods for research study/clinical trials design, engagement, and implementation.Methods:Participants were as follows: (1) parents of a child (<18 years) with POMS enrolled in a national registry, (2) adolescents (13–17 years) with POMS in the registry, and (3) adults (18–40 years) with POMS receiving care at a registry affiliated clinic. Of 293 eligible participants, 192 completed surveys.Results:Experiences with health care and medications were generally positive but there remain areas of priority improvement. Incentives to participate in clinical trials included medications previously tested and in pill form, bloodwork/study visits required ⩾ every 3 months, cognitive testing ⩽1 hour, compensation for travel and time, ability to continue current multiple sclerosis (MS) medication, option to take study medication if on placebo, and individualized study feedback. Priorities for clinical research were (1) psychosocial impact, (2) cognitive/academic impact, (3) environmental risk, and (4) nutrition.Conclusions:Results highlighted the importance of a holistic approach to study design and a focus on the impact of disease on daily life to best engage patients and families in POMS clinical trials and research.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
患者和家属对儿科多发性硬化症研究重点以及临床试验和研究设计的看法
背景与目标:本调查研究旨在(1)确定儿科发病型多发性硬化症(POMS)患者/家庭的研究重点;(2)确定研究/临床试验设计、参与和实施的优化方法:(方法:参与者包括:(1)在国家登记处登记的POMS患儿(18岁)的父母;(2)在登记处登记的POMS青少年(13-17岁);(3)在登记处附属诊所接受治疗的POMS成人(18-40岁)。在293名符合条件的参与者中,有192人完成了调查。结果显示:人们对医疗保健和药物治疗的体验总体上是积极的,但仍有需要重点改进的地方。参加临床试验的激励措施包括:之前测试过的药片形式的药物、每 3 个月⩾ 次的血液检查/研究访问、⩽ 1 小时的认知测试、差旅和时间补偿、继续服用当前多发性硬化症(MS)药物的能力、服用安慰剂时可选择服用研究药物以及个性化的研究反馈。临床研究的重点是:(1)社会心理影响;(2)认知/学业影响;(3)环境风险;以及(4)营养。结论:研究结果凸显了采用综合方法进行研究设计以及关注疾病对日常生活的影响对患者和家属参与POMS临床试验和研究的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Multiple Sclerosis Journal
Multiple Sclerosis Journal 医学-临床神经学
CiteScore
10.90
自引率
6.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585
期刊最新文献
Cryptogenic organising pneumonia in patients treated with ocrelizumab. Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review. Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study. Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies. Development and initial validation of the Cognitive Change Scale (CCS).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1